Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

Inclusion Criteria:

• Males and females of ≥6 and <18 years of age at time of consent

• Non-infectious posterior, intermediate or panuveitis in the study eye with a historyof recurrence ≥1 per year as assessed by the Investigator

• Uveitis in the study eye not adequately controlled by the preferred standard of caredue to intolerable adverse effects or poor response, in the judgment of theInvestigator

• Treatment with systemic corticosteroid or other systemic therapies given for atleast 3 months within the previous 12 months prior to Day 1

Exclusion Criteria:

• History of intraocular surgery in the study eye within 90 days of the screeningvisit.

• Hypersensitivity to FA or any component of ILUVIEN®

• History of any form of glaucoma or ocular hypertension in study eye, unless studyeye has been previously treated with an incisional IOP-lowering surgical procedureat least 90 days prior to the screening visit and that procedure has resulted instable IOP in the normal range (10-21 mmHg)

• Increased intraocular pressure >25 mmHg or that required treatment includingincreases in medications, surgery (other than drainage surgery), orhospitalisations, within 4 weeks prior to baseline that, in the opinion of theInvestigator, would pose an unacceptable risk to the patient participating in thestudy